NEOS Investment Management LLC Buys 23,291 Shares of Boston Scientific Corporation $BSX

NEOS Investment Management LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 10.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 243,837 shares of the medical equipment provider’s stock after purchasing an additional 23,291 shares during the quarter. NEOS Investment Management LLC’s holdings in Boston Scientific were worth $10,407,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the fourth quarter worth $26,000. Sfam LLC bought a new stake in Boston Scientific during the fourth quarter valued at $29,000. Finally, South Plains Financial Inc. bought a new stake in Boston Scientific during the fourth quarter valued at $39,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on BSX shares. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Mizuho lowered their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. TD Cowen reiterated a “buy” rating and set a $56.00 target price on shares of Boston Scientific in a research report on Tuesday, August 25th. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Price Performance

BSX stock opened at $47.85 on Friday. The stock has a market capitalization of $69.35 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 1.10 and a beta of 0.57. The firm’s 50-day moving average price is $46.90 and its two-hundred day moving average price is $55.74. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has initiated a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.